Abstract: The present disclosure relates to an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. An electrolyte solution for a lithium secondary battery includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes a positive-electrode film additive, which is 3-(4-cyano-5-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl methanesulfonate.

Abstract: The present disclosure relates to an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. An electrolyte solution for a lithium secondary battery includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes a first electrode film additive, which is 3-(4-cyano-5-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl 4-methylbenzenesulfonate.

Abstract: The present invention relates to a composition for nucleus-independent, sustained inhibition of gene expression, comprising an mRNA fragment of T7 RNA polymerase, plasmid DNA for self-amplification of the T7 RNA polymerase, and a DNA fragment encoding a gene expression inhibitor; a transporter of the gene expression inhibitor comprising the composition; and a method of preparing the transporter. The composition of the present invention and the liposome transporter of the present invention comprising the composition can improve the expression of shRNA in the cytoplasm through self-amplification of nucleus-independent, sustained self-amplification of T7 RNA polymerase, and deliver them in a cancer tissue-specific manner. Therefore, the composition and the liposome transporter of the present invention can be utilized for use in treating chronic diseases that require reduced frequency of administration and long-term inhibition of gene expression.

Abstract: Disclosed is a bio-inorganic hybrid composite for retaining and carrying bio-materials with stability and reversible dissociativity, represented by the following chemical Formula I and a method for preparing the same. The bio-inorganic hybrid composite is prepared by (a) coprecipitating with an alkaline material an aqueous solution comprising a bivalent metal (M(II)) and a trivalent metal (N(III)) at a molar ratio satisfying the condition of ⅕≦b/(a+b)≦½ wherein a and b represent a mole number of M and N, respectively, to form a stable layered double hydroxide in which anions are intercalated and (b) subjecting the intercalated anions to ion exchange reaction with a bio-material to compensate for layer charges of the layered double hydroxide. This composite is harmless to the body and artificially controls the appropriate expression of the bio-material retained therein. [M2+1−xN3+x(Oh)2][ABIOn−]x/n.